GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » 3-Year EPS without NRI Growth Rate

Geovax Labs (Geovax Labs) 3-Year EPS without NRI Growth Rate : 23.60% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs 3-Year EPS without NRI Growth Rate?

Geovax Labs's EPS without NRI for the three months ended in Dec. 2023 was $-3.94.

During the past 3 years, the average EPS without NRI Growth Rate was 23.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Geovax Labs was 99.70% per year. The lowest was -21843.50% per year. And the median was 7.40% per year.


Competitive Comparison of Geovax Labs's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Geovax Labs's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Geovax Labs's 3-Year EPS without NRI Growth Rate falls into.



Geovax Labs 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Geovax Labs  (NAS:GOVX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Geovax Labs 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Geovax Labs's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (Geovax Labs) Business Description

Industry
Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Executives
Mckee Kelly T. Jr. officer: Chief Medical Officer 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd director C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds officer: Chief Financial Officer TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan director 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey officer: VP, Business Development 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas director 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally director
Farshad Guirakhoo officer: Sr VP, Research & Development 39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi director 10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson other: Chair, Scientific Adv Brd 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman officer: VP, Research & Development 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas director 123 JOAN DRIVE, BARRINGTON IL 60010